Michael F. Mahoney deployed ~$10.0 million on August 3, 2026, to acquire ~200,000 shares at a weight

MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will par

Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and d

Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt

Boston Scientific ( BSX ) manufactures medical devices and products used in various interventional m

First National Bank of Mount Dora Trust Investment Services purchased a new stake in Boston Scientif

After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analyst

Bank of America Corp DE trimmed its position in Boston Scientific Corporation (NYSE: BSX) by 9.4% in

UBS analyst Patrick Wood maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price t

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading throm

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the

RBC Capital analyst Kendall Au maintains Boston Scientific (NYSE:BSX) with a Outperform and lower

TD Cowen analyst Joshua Jennings maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and

BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and n

Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:BSX) with a Outperform a

Boston Scientific retains my buy rating with a $66 price target, reflecting 44% upside if negative e

Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight an

Boston Scientific NYSE: BSX reported second-quarter 2026 revenue growth at the high end of its guida

BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the pric

Organic Sales Growth: 7% in Q2 2026, driven by Interventional Cardiology, Endoscopy, and Neuromodula

Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst e

Boston Scientific Corporation (BSX) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed

Boston Scientific Corporation (NYSE:BSX) stock is trading lower after the company cut its fiscal 202

Boston Scientific beat second-quarter estimates but lowered its 2026 sales and earnings outlook as r

BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, an

Boston Scientific (BSX) came out with quarterly earnings of $0.86 per share, beating the Zacks Conse

Boston Scientific Corp (NYSE:BSX, XETRA:BSX) reported second quarter results that exceeded analyst e

Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a

Boston Scientific (NYSE:BSX) is looking for Q3 Adj EPS of $0.80-$0.82 vs $0.83 analyst estimate. see

Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.34-$3.41 to $3.28-$3.32 vs $3.36

Boston Scientific (NYSE:BSX) reported quarterly earnings of $0.86 per share which beat the analyst c

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.23% on an annua

Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowe

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and

Mizuho analyst Anthony Petrone maintains Boston Scientific (NYSE:BSX) with a Outperform and lower

RBC Capital analyst Shagun Singh maintains Boston Scientific (NYSE:BSX) with a Outperform and low

July brings a sharp rotation trade in markets as investors shift from top performers to beaten-down

Needham analyst Mike Matson maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the pric

Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:BSX) with a Outperform a

Stifel analyst Rick Wise maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price t

Jefferies analyst Matthew Taylor maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.07% on an annua

Jim Cramer recommends buying SOFI, and avoiding RIVN and BSX. He also says NIOBF is too speculative,

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and

BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the pric

Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and